… In this study, we performed an epidemiological survey of the COVID-19 incidence in … , we
identified 11 confirmed COVID-19 cases in adults and no cases in the paediatric population. …

… a small incidence of COVID-19 … anti-rheumatic drugs may modulate inflammation and avoid
a hyperinflammation that leads to severe complications and death in subjects with COVID-19 …

… Early observational studies from longitudinal clinics reported similar incidence of COVID-19
among rheumatic disease patients vs. the general population [28,29,30,31]. Although these …

… erythrocyte sedimentation rate (… COVID-19 and management is largely supportive. However,
in light of the growing understanding of SARS-CoV-2 and COVID-19 biology, several drugs …

… disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of …
anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency …

… ) in patients with rheumatic diseases treated with targeted synthetic or biologic disease-modifying
antirheumatic drugs (DMARDs) compared with that in the general population living in …

… to obtain information on ongoing treatments with disease-modifying antirheumatic drugs (DMARDs)
including conventional DMARDs, biologics and glucocorticoids [12]. Patients with …

… the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts/bDMARDs)
and other variables in the development of moderate-severe COVID-19 disease in IRD. …

… drugs during the COVID-19 pandemics remains questionable, and the prevalence of COVID-19
… on long-term DMARD therapy were not at a higher risk of COVID-19 infection than the …

… immunosuppressive disease-modifying anti-rheumatic drugs (DMARDs) to control disease
… The overall COVID-19 infection rate in our rheumatic patients treated with bDMARDs or …